Reinders Floris C J, Heijst Tristan C F van, Mases Joel, Terhaard Chris H J, Doornaert Patricia A H, Philippens Marielle E P, Raaijmakers Cornelis P J
Department of Radiotherapy, University Medical Centre Utrecht, the Netherlands.
Phys Imaging Radiat Oncol. 2021 Nov 10;20:76-81. doi: 10.1016/j.phro.2021.10.006. eCollection 2021 Oct.
Conventional elective neck irradiation (ENI) in head and neck cancer consists of radiotherapy (RT) to the regional lymph node (LN) levels contoured on computed tomography. Hybrid Magnetic Resonance (MR) - RT modalities, such as combined magnetic resonance imaging - linear accelerators (MRLs), might enable new ENI strategies in which individual non-suspect lymph nodes (i-LNs) are targeted. In this treatment planning study, new MR-based strategies targeting i-LNs (i-ENI) were compared to conventional treatment.
All i-LNs were delineated on MR images of ten retrospectively selected patients with T2-4aN0M0 laryngeal cancer. Three strategies were considered. Strategy A: Conventional ENI delivered with a conventional linear accelerator (35x 1.55 Gy). Strategy B: MRL-based i-ENI (35x 1.55 Gy) to the individual lymph nodes including a background dose to the conventional elective neck volumes (35x 1.03 Gy). Strategy C: Same as Strategy B, but without background dose. In all plans the dose prescription to the primary tumor was 35x 2 Gy. Mean dose ( ) reductions in the organs at risk (OAR) were compared using the Wilcoxon signed rank test.
Compared to conventional ENI (strategy A), significant reductions of 6.0 Gy and 8.0 Gy were observed in the submandibular glands, of 9.4 Gy and 13 Gy in the carotid arteries and of 9.9 Gy and 19.4 Gy in the thyroid for strategy B and C, respectively. Large inter-patient variations of reductions were observed in all OARs.
MRL-based i-ENI is a new promising concept that could reduce the mean dose to OARs in the neck significantly for patients with laryngeal cancer.
头颈部癌的传统选择性颈部照射(ENI)包括对计算机断层扫描所勾勒出的区域淋巴结(LN)水平进行放射治疗(RT)。混合磁共振(MR)-RT模式,如联合磁共振成像-直线加速器(MRL),可能会催生新的ENI策略,即针对单个非可疑淋巴结(i-LN)进行靶向治疗。在这项治疗计划研究中,将基于MR的针对i-LN的新策略(i-ENI)与传统治疗进行了比较。
在十例回顾性选择的T2-4aN0M0喉癌患者的MR图像上勾勒出所有i-LN。考虑了三种策略。策略A:使用传统直线加速器进行传统ENI(35×1.55 Gy)。策略B:基于MRL的i-ENI(35×1.55 Gy)针对单个淋巴结,并对传统选择性颈部体积给予背景剂量(35×1.03 Gy)。策略C:与策略B相同,但不给予背景剂量。在所有计划中,对原发肿瘤的剂量处方为35×2 Gy。使用Wilcoxon符号秩检验比较危险器官(OAR)中平均剂量( )的降低情况。
与传统ENI(策略A)相比,策略B和C在下颌下腺中的平均剂量分别显著降低了6.0 Gy和8.0 Gy,在颈动脉中分别降低了9.4 Gy和13 Gy,在甲状腺中分别降低了9.9 Gy和19.4 Gy。在所有OAR中均观察到患者间平均剂量降低的较大差异。
基于MRL的i-ENI是一个新的有前景的概念,对于喉癌患者可显著降低颈部OAR的平均剂量。